Hangzhou Yirui Pharmaceutical Technology Co. Ltd. has described N-tetrazolyl aryl urea derivatives acting as bradykinin B1 receptor antagonists reported to be useful for the treatment of age-related macular degeneration, allergic conjunctivitis, pulmonary edema, neuralgia, infectious pneumonia, diabetic retinopathy, SARS-CoV-2 infection (COVID-19) and uveitis.

Treeline Biosciences Inc. has divulged proteolysis targeting chimeras (PROTACs) compounds comprising a cereblon (CRBN) binding moiety covalently bonded to a B-cell lymphoma 6 protein (BCL6) targeting moiety through a linker reported to be useful for the treatment of cancer.

Mirati Therapeutics Inc. has identified compounds acting as GTPase KRAS and/or GTPase KRAS (mutant) inhibitors reported to be useful for the treatment of cancer.

Researchers at Aston Science Co. Ltd. and Korea Research Institute of Chemical Technology have synthesized phenylsulfonamide derivatives acting as eukaryotic translation initiation factor 2-α kinase 1 (HRI) and/or translation initiation factor 2-α kinase 3 (PERK) and/or eukaryotic translation initiation factor 2-α kinase 4 (GCN2) inhibitors reported to be useful for the treatment of cancer.

Guangzhou Fermion Technology Co. Ltd. has disclosed non-receptor tyrosine-protein kinase TYK2 (JH2 domain) inhibitors reported to be useful for the treatment of cancer, asthma and more.

Researchers at Hitgen Ltd. and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. have described Bcl-2-like protein 1 (Bcl-xL; Bcl-X; BCL2L1) inhibitors reported to be useful for the treatment of cancer and autoimmune diseases.

Sutro Biopharma Inc. has divulged stimulator of interferon genes protein (STING; TMEM173) agonists reported to be useful for the treatment of cancer.

RTI International has identified squaramide derivatives acting as cannabinoid CB1 receptor allosteric modulators reported to be useful for the treatment of obesity and substance abuse and dependence.

University of Antwerp has synthesized dipeptidyl peptidase IX (DPP9; DPRP2) inhibitors reported to be useful for the treatment of cancer.

Domain Therapeutics SA has disclosed proteinase-activated receptor 2 (PAR2; F2RL1) antagonists reported to be useful for the treatment of allergy, autoimmune and metabolic diseases, cardiovascular disorders, dermatological disorders, inflammatory disorders, pain and cancer.